+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years - 100Years
MALE
ID06044025

Feasibility Study of Adding Metformin and Turmeric to Intermittent Androgen Deprivation Therapy for Men with Biochemically Progressive Castration Sensitive Prostate Cancer

Led by University of Arkansas · Updated on 2026-10-15

34

Participants Needed

1

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the feasibility of adding a combination of metformin and turmeric to the current standard intermittent Androgen Deprivation Therapy iADT for patients with castration sensitive biochemical progressive prostate cancer. The study aims to assess the enrollment feasibility and evaluate the time to PSA relapse with this nutritional intervention alongside iADT. The long-term goal is to explore the roles of metabolic syndrome, microenvironment, microbiome, and genomic versus epigenomic profiles in the care of these patients. Participants will receive the standard iADT treatment along with metformin and turmeric supplements. Metformin dosing starts at 500 mg twice daily with meals for 14 days, increasing to 850 mg twice daily for another 14 days, then titrated up to 1,000 mg twice daily. Participants already on metformin will continue or adjust their dose accordingly. After two weeks of metformin titration, turmeric is introduced at 1,500 mg daily with meals, with the possibility to reduce to 1,000 mg daily if gastrointestinal discomfort occurs. If discomfort persists, participants may stop the study treatment. During the study, participants will complete a pill diary and provide blood and stool samples for research on biomarkers and microbiome profiles. Quality of life is assessed using the Functional Assessment of Cancer Therapy-Prostate FACT-P and the Aging Male Symptoms AMS questionnaires. Standard laboratory tests will follow clinical practice for prostate cancer care. The study monitors recruitment feasibility and PSA relapse time over up to 27 months, with overall participation lasting until study completion in 2028.

CONDITIONS

Brief Title

A Feasibility Study Evaluating a Role for Maintenance Therapy in Patients With Biochemically Progressive Castration Sensitive Prostate Cancer on Intermittent Androgen Deprivation Therapy

Research Team

E

Emily Baker

A

Aaron Holley

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here